Skip to main content
Supplement ScienceSupplementScience

Vitamin B3 (Niacin) Research & Evidence

·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Strong

Vitamin B3 has a complex clinical profile. For cholesterol, niacin was a cornerstone therapy for decades, but the AIM-HIGH trial (2011, n=3,414) found no cardiovascular benefit when added to statin therapy, diminishing enthusiasm for high-dose niacin. For skin health, the ONTRAC trial by Chen et al. (2015, n=386) demonstrated that nicotinamide 500 mg twice daily reduced the incidence of new non-melanoma skin cancers by 23%. In aging research, Martens et al. (2018) showed that nicotinamide riboside (NR) at 1,000 mg/day raised NAD+ levels by approximately 60% and was well-tolerated in healthy older adults, though clinical outcome benefits remain under investigation.

Evidence by Condition

ConditionStudied DoseEvidence
General health14-16 mg NE dailyStrong
Cholesterol (niacin)1,000-3,000 mg nicotinic acid daily under medical supervisionStrong
Skin health (niacinamide)500 mg twice dailyStrong
NAD+ support (NR)250-1,000 mg nicotinamide riboside dailyEmerging

References

  1. RCTAIM-HIGH Investigators, Boden WE, Probstfield JL, et al. (2011). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine. DOI PubMed
  2. RCTChen AC, Martin AJ, Choy B, et al. (2015). A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. New England Journal of Medicine. DOI PubMed
  3. RCTMartens CR, Denman BA, Mazzo MR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. DOI PubMed